Trump Administration Used Compounding Pharmacies To Pressure Pharma Bros To Bring Down Pricing Of GLP1s In The US

The Trump administration’s aggressive push to reduce prescription med costs has had a measurable impact on the pricing of GLP-1 treatments in the United States, and compounding pharmacies played a central role in creating the competitive pressure that made it happen. In a recent episode of the Huberman Lab podcast, Dr. Abud Bakri, an internal … Read more

Neuroscientist Andrew Huberman Forced To Deny Conflict of Interest After Sudden Increased Interest Into Peptides

Stanford neuroscientist Andrew Huberman found himself on the defensive this week after a wave of audience skepticism followed his increasingly enthusiastic public commentary on peptides, forcing him to issue multiple denials of any financial ties to the pharma or peptide industries. The clarifications came after a noticeable shift in Huberman’s tone on the subject prompted … Read more